Latest updates for Axelar

Fresh curated links around Axelar are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Daraxonrasib shows early antitumor activity in RAS-mutant lung cancer
  • Akeso, Summit cancer drug confirms lung cancer survival benefit
  • New Taiho, Cullinan data heats up lung cancer drug battle

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

bioengineer.org /2 days ago

Daraxonrasib shows early antitumor activity in RAS-mutant lung cancer

Daraxonrasib, Revolution Medicines tarafД±ndan geliЕџtirilen deneysel bir oral RAS inhibitГ¶rГј, ameliyat dД±ЕџД± NSCLC olgularД±nД±n yaklaЕџД±k ГјГ§te birini oluЕџturan ve PD-1 ek...

Read source
biopharmadive.com /6 days ago

Akeso, Summit cancer drug confirms lung cancer survival benefit

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

Read source
biopharmadive.com /3 weeks ago

New Taiho, Cullinan data heats up lung cancer drug battle

The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering Axelar

bioengineer.org

Recent coverage from public sources
Public source

biopharmadive.com

Recent coverage from public sources
Public source

Related searches